Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Plasmid DNA Manufacturing Market, by Product Type (High Quality (HQ) Plasmid DNA, GMP Grade Plasmid DNA, and Non-GMP Grade Plasmid DNA), by Application (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 65.1 million in 2017 and is estimated to exhibit a CAGR of 23.7% over the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2593
Increased research and development activity is expected to augment the market growth over the forecast period.
Major market players are focusing on research & development, expansion, and collaborations activities, in order to strengthen their position in the global market. For instance, in January 2019, Sarepta Therapeutics, Inc. and Aldevron entered into a collaboration. This collaboration offered Sarepta with Aldevron’s manufacturing slots and capacity for production of GMP grade plasmid for its various programs related to gene therapy. For instance, in January 2019, Sarepta Therapeutics, Inc. collaborated with Aldevron to supply GMP grade plasmids, in order to cater to increasing demand of Sarepta’s gene therapy clinical trials and for commercial supply.
Moreover, in April 2018, PlasmidFactory GmbH & Co. KG acquired new laboratory space to expand research and development activities and production of plasmid DNA. This strategic move was initiated, attributed to increasing demand for High Quality (HQ) Grade DNA production.
Browse 36 Market Data Tables and 32 Figures spread through 149 Pages and in-depth TOC on ‘Plasmid DNA Manufacturing Market’- Global Forecast to 2026, by Product Type (High Quality (HQ) Plasmid DNA, GMP Grade Plasmid DNA, and Non-GMP Grade Plasmid DNA), by Application (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Plasmid DNA Manufacturing Market Press Release, click the link below: https://bit.ly/2GZ9ue1
Moreover, major market players are focused on adopting growth strategies such as mergers, acquisitions, and partnerships to expand their product portfolio. For instance, in February 2016, Agilis Biotherapeutics, LLC (Agilis) and Waisman Biomanufacturing entered into an exclusive partnership agreement for the production of Agilis’ novel gene therapy product, AGIL-FA, indicated for the treatment of Friedreich’s ataxia (FA).
Similarly, Aldevron announced about expansion plan for antibody development platform facility in Germany, in March 2019. This expansion plan will add around 4,300 square feet of production and laboratory space to current facility.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2593
Key Takeaways of the Plasmid DNA Manufacturing Market:
- The global plasmid DNA manufacturing market is expected to exhibit a CAGR of 23.7% over the forecast period, attributed to increasing demand for plasmid (pDNA) DNA
- On the basis of product type, high quality plasmid DNA segment accounted for a major market share in the plasmid DNA manufacturing market in 2017. The segment growth is attributed to increasing usage of higher quality plasmid DNA in biotechnology research and vaccine production
- On the basis of application, immunotherapy segment accounted for a major market share in the plasmid DNA manufacturing market in 2017, attributed to high adoption rate of immunotherapy
- Major players operating in the global plasmid DNA manufacturing market include Cobra Biologics and Pharmaceutical Services, VGXI, Inc., Aldevron, Kaneka Corporation, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, and Waisman Biomanufacturing
Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/2593
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
